TY - JOUR T1 - Total predicted MHC-I epitope load is inversely associated with mortality from SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.05.08.20095430 SP - 2020.05.08.20095430 AU - Eric A. Wilson AU - Gabrielle Herneise AU - Abhishek Singharoy AU - Karen S. Anderson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/12/2020.05.08.20095430.abstract N2 - Polymorphism in MHC-I protein sequences across human populations significantly impacts their binding to viral peptides and alters T cell immunity to infection. Prioritization of MHC-I restricted viral epitopes remains a fundamental challenge for understanding adaptive immunity to SARS-CoV-2. Here, we present a consensus MHC-I binding prediction model, EnsembleMHC, based on the biochemical and structural basis of peptide presentation to aid the discovery of SARS-CoV-2 MHC-I peptides. We performed immunopeptidome predictions of SARS-CoV-2 proteins across 52 common MHC-I alleles identifying 658 high confidence peptides. Analysis of the resulting peptide-allele assignment distribution demonstrated significant variation across the allele panel up to an order of magnitude. Using MHC-I population-based allele frequencies, we estimated the average SARS-CoV-2 peptide population binding capacity across 21 individual countries. We have discovered a strong inverse association between the predicted population SARS-CoV-2 peptide binding capacity and overall mortality. Furthermore, we found that the consideration of only structural proteins produced a stronger association with observed death rate, highlighting their importance in protein-targeted immune responses. The 108 predicted SARS-CoV-2 structural protein peptides were shown to be derived from enriched regions in the originating protein, and present minimal risk for disruption by mutation. These results suggest that the immunologic fitness of both individuals and populations to generate class I-restricted T cell immunity to SARS-CoV-2 infection may impact clinical outcome from viral infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHLA frequency data was obtained from the Allele Frequency Net database. Coronavirus pandemic information was obtained from the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Mass spectrometry data was obtained from the UCSD MASSive database (MSV000084442). SARS-CoV-2 sequences were obtained from NCBI Virus database. http://www.allelefrequencies.net https://github.com/CSSEGISandData/COVID-19.git https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/ ER -